Immunotherapy trials in mesothelioma — promising results, but don’t stop here
Nature Reviews Clinical Oncology, Published online: 17 October 2019; doi:10.1038/s41571-019-0291-4In the past few years, several studies have addressed the possibility of using immunotherapies to treat patients with mesothelioma. Herein, we discuss two recent trials, one testing the immune-checkpoint inhibitor nivolumab and the other testing a mesothelin-directed therapeutic vaccine, and reflect on the advances and challenges remaining in this research area. (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - October 17, 2019 Category: Cancer & Oncology Authors: Anna K. Nowak Patrick M. Forde Source Type: research

From the ESMO Congress 2019
Nature Reviews Clinical Oncology, Published online: 16 October 2019; doi:10.1038/s41571-019-0292-3From the ESMO Congress 2019 (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - October 16, 2019 Category: Cancer & Oncology Authors: Peter Sidaway Source Type: research

A systems approach to clinical oncology uses deep phenotyping to deliver personalized care
Nature Reviews Clinical Oncology, Published online: 16 October 2019; doi:10.1038/s41571-019-0273-6A systems biology-based approach incorporating multiscale, longitudinal measurements (from single-cell analyses to whole-body monitoring) would help to decipher the complexity of cancer and would facilitate the development of personalized therapies. The authors of this Perspective discuss how systems biology-based approaches can provide data for early detection of disease transitions, prediction of therapeutic responses and clinical outcomes, and for the design of personalized treatments. (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - October 16, 2019 Category: Cancer & Oncology Authors: James T. Yurkovich Qiang Tian Nathan D. Price Leroy Hood Source Type: research

Nivolumab effective in oesophageal carcinoma
Nature Reviews Clinical Oncology, Published online: 15 October 2019; doi:10.1038/s41571-019-0289-yNivolumab effective in oesophageal carcinoma (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - October 15, 2019 Category: Cancer & Oncology Authors: Diana Romero Source Type: research

Combinations provide sustained benefit
Nature Reviews Clinical Oncology, Published online: 11 October 2019; doi:10.1038/s41571-019-0290-5Combinations provide sustained benefit (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - October 11, 2019 Category: Cancer & Oncology Authors: Peter Sidaway Source Type: research

CDK4/6 inhibitors prolong OS
Nature Reviews Clinical Oncology, Published online: 11 October 2019; doi:10.1038/s41571-019-0288-zCDK4/6 inhibitors prolong OS (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - October 11, 2019 Category: Cancer & Oncology Authors: David Killock Source Type: research

BEACON of hope in BRAFV600E CRC
Nature Reviews Clinical Oncology, Published online: 10 October 2019; doi:10.1038/s41571-019-0286-1BEACON of hope in BRAFV600E CRC (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - October 10, 2019 Category: Cancer & Oncology Authors: David Killock Source Type: research

Oncolysis without viruses — inducing systemic anticancer immune responses with local therapies
Nature Reviews Clinical Oncology, Published online: 08 October 2019; doi:10.1038/s41571-019-0272-7Oncolytic viruses are beginning to enter clinical use in patients with cancer despite regulatory and practical considerations precluding the widespread use of such therapies. Here, the authors describe the potential of non-viral methods in achieving oncolytic effects and how these effects might prime the development of antitumour immune responses in patients with cancer. (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - October 8, 2019 Category: Cancer & Oncology Authors: Oliver Kepp Aurelien Marabelle Laurence Zitvogel Guido Kroemer Source Type: research

Why BRCA mutations are not tumour-agnostic biomarkers for PARP inhibitor therapy
Nature Reviews Clinical Oncology, Published online: 03 October 2019; doi:10.1038/s41571-019-0285-2BRCA1/2 mutations and poly (ADP-ribose) polymerase (PARP) inhibitors are paradigmatic of synthetic lethal therapy. However, the activity of PARP inhibitors seems to vary considerably across BRCA1/2-mutant cancers and new insights into the tumour-lineage dependency of this synthetic lethal relationship might explain why BRCA1/2 mutations are not tumour-agnostic biomarkers of a response to PARP inhibitors. (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - October 3, 2019 Category: Cancer & Oncology Authors: Nicola J. Curtin Yvette Drew Sweta Sharma-Saha Source Type: research

What to expect from AI in oncology
Nature Reviews Clinical Oncology, Published online: 01 October 2019; doi:10.1038/s41571-019-0283-4What to expect from AI in oncology (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - October 1, 2019 Category: Cancer & Oncology Source Type: research

Combining epigenetic drugs with other therapies for solid tumours — past lessons and future promise
Nature Reviews Clinical Oncology, Published online: 30 September 2019; doi:10.1038/s41571-019-0267-4The use of epigenetic drugs (epi-drugs) as single agents according to a ‘one size fits all’ approach has generally resulted in disappointing therapeutic activity. In this Review, the mechanisms by which epi-drugs can modulate the sensitivity of cancer cells to other diverse forms of anticancer therapy are described, and completed and ongoing clinical trials relating to combination therapies incorporating epi-drugs are discussed. In addition, clinical trial designs and drug development strategies aimed at optimizi...
Source: Nature Reviews Clinical Oncology - September 30, 2019 Category: Cancer & Oncology Authors: Daphn é Morel Daniel Jeffery Sandrine Aspeslagh Genevi ève Almouzni Sophie Postel-Vinay Source Type: research

Paradoxical roles of mutational load as a determinant of anticancer immunity
Nature Reviews Clinical Oncology, Published online: 27 September 2019; doi:10.1038/s41571-019-0282-5Paradoxical roles of mutational load as a determinant of anticancer immunity (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - September 27, 2019 Category: Cancer & Oncology Authors: David Killock Source Type: research

Liquid outperforms tissue
Nature Reviews Clinical Oncology, Published online: 24 September 2019; doi:10.1038/s41571-019-0279-0Liquid outperforms tissue (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - September 24, 2019 Category: Cancer & Oncology Authors: Diana Romero Source Type: research

The emerging role of epigenetic therapeutics in immuno-oncology
Nature Reviews Clinical Oncology, Published online: 23 September 2019; doi:10.1038/s41571-019-0266-5Despite promising responses in a minority of patients with cancer, considerable scope remains to improve the efficacy of both immune-checkpoint inhibitors and epigenetic drugs, with one potential strategy involving the combination of these two types of treatment. Here, the authors describe the mechanisms underlying the synergy between immune-checkpoint inhibitors and epigenetic drugs and discuss the ongoing clinical development of such combinations. (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - September 23, 2019 Category: Cancer & Oncology Authors: Michael J. Topper Michelle Vaz Kristen A. Marrone Julie R. Brahmer Stephen B. Baylin Source Type: research

HER2-targeted therapies — a role beyond breast cancer
Nature Reviews Clinical Oncology, Published online: 23 September 2019; doi:10.1038/s41571-019-0268-3HER2-targeted therapies have dramatically improved the outcomes in women with HER2-positive breast cancer. Furthermore, genetic sequencing studies have revealed HER2 alterations in a range of other cancers, including gastric cancer, colorectal cancer and non-small-cell lung cancer. In this Review the authors describe the available data on HER2-targeted therapies beyond breast cancer. (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - September 23, 2019 Category: Cancer & Oncology Authors: Do-Youn Oh Yung-Jue Bang Source Type: research

Combining immunotherapy and radiotherapy for the STAR treatment
Nature Reviews Clinical Oncology, Published online: 20 September 2019; doi:10.1038/s41571-019-0277-2In the past few years, efforts have been made to combine two approaches — immune-checkpoint inhibition and locally ablative radiation therapy — to treat patients with metastatic non-small-cell lung cancer. Herein we discuss the implications of two studies that support the existence of a systemic therapy augmented by radiotherapy (STAR) effect in this setting. (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - September 20, 2019 Category: Cancer & Oncology Authors: Jordan A. Torok Joseph K. Salama Source Type: research

From New directions in immuno-oncology
Nature Reviews Clinical Oncology, Published online: 20 September 2019; doi:10.1038/s41571-019-0280-7From New directions in immuno-oncology (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - September 20, 2019 Category: Cancer & Oncology Authors: Diana Romero Source Type: research

Microbes as biomarkers and targets in pancreatic cancer
Nature Reviews Clinical Oncology, Published online: 17 September 2019; doi:10.1038/s41571-019-0276-3The presence and prognostic relevance of the intratumoural microbiota in pancreatic cancer, and the roles of intratumoural bacteria in oncogenesis and therapeutic response are beginning to be elucidated. The feasibility of characterizing intratumoural microbial communities from paraffin-embedded tissues has now been validated, providing greater opportunities for retrospective research. Prospective studies are also needed to test the efficacy of rational approaches combining microbial modulation with chemotherapy and/or immun...
Source: Nature Reviews Clinical Oncology - September 17, 2019 Category: Cancer & Oncology Authors: Joshua C. Leinwand George Miller Source Type: research

CD19 affinity — is lower also better?
Nature Reviews Clinical Oncology, Published online: 13 September 2019; doi:10.1038/s41571-019-0278-1CD19 affinity — is lower also better? (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - September 13, 2019 Category: Cancer & Oncology Authors: Peter Sidaway Source Type: research

Responses to selinexor in multiple myeloma
Nature Reviews Clinical Oncology, Published online: 04 September 2019; doi:10.1038/s41571-019-0275-4Responses to selinexor in multiple myeloma (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - September 4, 2019 Category: Cancer & Oncology Authors: Diana Romero Source Type: research

DYNAMIC insights into MRD responses early after resection of NSCLC
Nature Reviews Clinical Oncology, Published online: 04 September 2019; doi:10.1038/s41571-019-0274-5DYNAMIC insights into MRD responses early after resection of NSCLC (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - September 4, 2019 Category: Cancer & Oncology Authors: David Killock Source Type: research

Phase I trials as valid therapeutic options for patients with cancer
Nature Reviews Clinical Oncology, Published online: 02 September 2019; doi:10.1038/s41571-019-0262-9Oncology phase I trials have been traditionally referred to as ‘toxicity trials’. The distinction of clinical trials into three phases has been challenged in the past few years, leading to the current situation in which response rates are increasingly reported from phase I trials. The authors dissect the ethical dilemmas surrounding the therapeutic intent of phase I trials and provide evidence of contemporary phase I trials as a therapeutic option for patients with cancer. (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - September 2, 2019 Category: Cancer & Oncology Authors: Jacob J. Adashek Patricia M. LoRusso David S. Hong Razelle Kurzrock Source Type: research

A new standard for EGFR-mutant NSCLC?
Nature Reviews Clinical Oncology, Published online: 30 August 2019; doi:10.1038/s41571-019-0271-8A new standard for EGFR-mutant NSCLC? (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - August 30, 2019 Category: Cancer & Oncology Authors: David Killock Source Type: research

Phase I trials as therapeutic options: (usually) a betrayal of evidence-based medicine
Nature Reviews Clinical Oncology, Published online: 30 August 2019; doi:10.1038/s41571-019-0264-7Many argue that phase I cancer trials are a therapeutic option for eligible patients. I question this position and offer a more nuanced view that differentiates between types of trials. Patients seeking treatment might legitimately pursue phase I trials, although labelling all phase I trials as therapeutic contradicts the spirit of evidence-based medicine. (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - August 30, 2019 Category: Cancer & Oncology Authors: Jonathan Kimmelman Source Type: research

WEE1 kinase inhibitor shows promise
Nature Reviews Clinical Oncology, Published online: 27 August 2019; doi:10.1038/s41571-019-0270-9WEE1 kinase inhibitor shows promise (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - August 27, 2019 Category: Cancer & Oncology Authors: Peter Sidaway Source Type: research

Personalized MRD assays and therapy?
Nature Reviews Clinical Oncology, Published online: 21 August 2019; doi:10.1038/s41571-019-0269-2Personalized MRD assays and therapy? (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - August 21, 2019 Category: Cancer & Oncology Authors: David Killock Source Type: research

Ibrutinib outperforms FCR in CLL
Nature Reviews Clinical Oncology, Published online: 15 August 2019; doi:10.1038/s41571-019-0265-6Ibrutinib outperforms FCR in CLL (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - August 15, 2019 Category: Cancer & Oncology Authors: Diana Romero Source Type: research

New targeted agents for urothelial carcinoma
Nature Reviews Clinical Oncology, Published online: 12 August 2019; doi:10.1038/s41571-019-0263-8New targeted agents for urothelial carcinoma (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - August 12, 2019 Category: Cancer & Oncology Authors: Peter Sidaway Source Type: research

Artificial intelligence in digital pathology — new tools for diagnosis and precision oncology
Nature Reviews Clinical Oncology, Published online: 09 August 2019; doi:10.1038/s41571-019-0252-yThe authors of this Perspective critically evaluate various artificial intelligence (AI)-based computational approaches used for digital pathology and provide a broad framework to incorporate these tools into clinical oncology, discussing challenges such as the need for well-curated validation datasets, regulatory approval and fair reimbursement strategies. (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - August 9, 2019 Category: Cancer & Oncology Authors: Kaustav Bera Kurt A. Schalper David L. Rimm Vamsidhar Velcheti Anant Madabhushi Source Type: research

Deglycosylated PD-L1 might be a better biomarker
Nature Reviews Clinical Oncology, Published online: 06 August 2019; doi:10.1038/s41571-019-0261-xDeglycosylated PD-L1 might be a better biomarker (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - August 6, 2019 Category: Cancer & Oncology Authors: Peter Sidaway Source Type: research

Global Consultation on Cancer Staging: promoting consistent understanding and use
Nature Reviews Clinical Oncology, Published online: 06 August 2019; doi:10.1038/s41571-019-0253-xAttempts to incorporate additional criteria into the traditional tumour-node-metastasis staging classification have often resulted in inaccuracy and confusion in the use of terminology. In this Position paper, the authors provide guidance on the consistent use of the terminology relating to cancer staging. (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - August 6, 2019 Category: Cancer & Oncology Authors: James Brierley Brian O ’Sullivan Hisao Asamura David Byrd Shao Hui Huang Anne Lee Marion Pi ñeros Malcolm Mason Fabio Y. Moraes Wiebke R ösler Brian Rous Julie Torode J. Han van Krieken Mary Gospodarowicz Source Type: research

A reality check of the accelerated approval of immune-checkpoint inhibitors
Nature Reviews Clinical Oncology, Published online: 05 August 2019; doi:10.1038/s41571-019-0260-yThe FDA grants Accelerated Approval when deemed necessary to address an unmet need, with a promise that post-marketing research commitments will be fulfilled and that the approvals will be revisited and eventually changed if clinically meaningful results are reported. Herein, we present a timeline of all Accelerated Approvals granted to immune-checkpoint inhibitors to illustrate three ways in which the FDA has failed to fulfil their part in this social contract. (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - August 5, 2019 Category: Cancer & Oncology Authors: Jennifer Gill Vinay Prasad Source Type: research

Comorbid chronic diseases and cancer diagnosis: disease-specific effects and underlying mechanisms
Nature Reviews Clinical Oncology, Published online: 26 July 2019; doi:10.1038/s41571-019-0249-6The majority of patients with cancer have at least one chronic health condition at the time of diagnosis. Nonetheless, how such conditions influence the timeliness of diagnosis remains largely unknown. In this Review the authors describe the available evidence on the complex relationships between cancer and other chronic diseases, and the implications for diagnosis and screening programmes. (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - July 26, 2019 Category: Cancer & Oncology Authors: Cristina Renzi Aradhna Kaushal Jon Emery Willie Hamilton Richard D. Neal Bernard Rachet Greg Rubin Hardeep Singh Fiona M. Walter Niek J. de Wit Georgios Lyratzopoulos Source Type: research

PERSEPHONE — implications for clinical practice in 2019
Nature Reviews Clinical Oncology, Published online: 24 July 2019; doi:10.1038/s41571-019-0256-7Five randomized trials have been conducted to prove that shorter duration of trastuzumab treatment (9 weeks or 6 months) can replace the standard duration (1 year). The results of PERSEPHONE, the most recent trial, suggest that the efficacy of a 6-month treatment is non-inferior to that of 1 year, although not for all patients. We discuss these results in the context of current treatment standards. (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - July 24, 2019 Category: Cancer & Oncology Authors: Noam Pond é Evandro de Azambuja Source Type: research

PARP inhibition — opportunities in pancreatic cancer
Nature Reviews Clinical Oncology, Published online: 22 July 2019; doi:10.1038/s41571-019-0257-6An urgent clinical need exists to improve the survival of patients with pancreatic cancer through biomarker-driven therapeutic strategies. Such approaches include the targeting of metastatic pancreatic cancer that harbours germline BRCA mutations with poly(ADP-ribose) polymerase inhibitors as maintenance therapy following platinum-based chemotherapy. (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - July 22, 2019 Category: Cancer & Oncology Authors: Shubham Pant Anirban Maitra Timothy A. Yap Source Type: research

Microenvironment plasticity confers cetuximab resistance
Nature Reviews Clinical Oncology, Published online: 19 July 2019; doi:10.1038/s41571-019-0259-4Microenvironment plasticity confers cetuximab resistance (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - July 19, 2019 Category: Cancer & Oncology Authors: Peter Sidaway Source Type: research

TKI-based on/off switch for CAR T cells
Nature Reviews Clinical Oncology, Published online: 16 July 2019; doi:10.1038/s41571-019-0258-5TKI-based on/off switch for CAR T cells (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - July 16, 2019 Category: Cancer & Oncology Authors: David Killock Source Type: research

Continuing to improve outcomes of men with metastatic prostate cancer
Nature Reviews Clinical Oncology, Published online: 16 July 2019; doi:10.1038/s41571-019-0254-9In the TITAN and ENZAMET trials, unprecedented overall survival outcomes were observed in patients with metastatic castration-sensitive prostate cancer receiving an agent targeting the androgen receptor in addition to androgen-deprivation therapy early in the course of their disease. Herein, I discuss both trials in the context of other studies in this disease setting. (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - July 16, 2019 Category: Cancer & Oncology Authors: Fred Saad Source Type: research

Immune-checkpoint inhibition as first-line therapy for Hodgkin lymphoma
Nature Reviews Clinical Oncology, Published online: 15 July 2019; doi:10.1038/s41571-019-0255-8The addition of the immune-checkpoint inhibitor nivolumab to first-line therapy with doxorubicin, vinblastine and dacarbazine seems feasible, with no signals of severe additional toxicities emerging. The high response rates and acceptable safety profile might make this combination an appealing alternative in the treatment of patients with high-risk disease. (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - July 15, 2019 Category: Cancer & Oncology Authors: Alvaro J. Alencar Craig H. Moskowitz Source Type: research

The era of alternative designs to connect randomized clinical trials and real-world data
Nature Reviews Clinical Oncology, Published online: 11 July 2019; doi:10.1038/s41571-019-0250-0The era of alternative designs to connect randomized clinical trials and real-world data (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - July 11, 2019 Category: Cancer & Oncology Authors: Jeroen W. G. Derksen Anne M. May Miriam Koopman Source Type: research

Biomarker-guided therapy for colorectal cancer: strength in complexity
Nature Reviews Clinical Oncology, Published online: 09 July 2019; doi:10.1038/s41571-019-0241-1“With the development of novel targeted therapies for patients with colorectal cancer, comes a wealth of new, and increasingly complex information on biomarkers. In this Review, the authors describe this increased complexity, with a focus on interactions between more than one biomarker and the implications of these interactions for patient management.” (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - July 9, 2019 Category: Cancer & Oncology Authors: Anita Sveen Scott Kopetz Ragnhild A. Lothe Source Type: research

T cell transfer after allo-HSCT in AML
Nature Reviews Clinical Oncology, Published online: 09 July 2019; doi:10.1038/s41571-019-0251-zT cell transfer after allo-HSCT in AML (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - July 9, 2019 Category: Cancer & Oncology Authors: Diana Romero Source Type: research

Chronic lymphocytic leukaemia: from genetics to treatment
Nature Reviews Clinical Oncology, Published online: 05 July 2019; doi:10.1038/s41571-019-0239-8In this Review, the authors present current insights into the genetic aetiology and pathogenesis of chronic lymphocytic leukaemia, highlighting the effect of recurrent lesions on progression, and discuss their clinical implications for management and development of novel therapeutic paradigmns. (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - July 5, 2019 Category: Cancer & Oncology Authors: Francesc Bosch Riccardo Dalla-Favera Source Type: research

ANNOUNCE prompts questions over the Accelerated Approval process
Nature Reviews Clinical Oncology, Published online: 27 June 2019; doi:10.1038/s41571-019-0246-9The negative results of the ANNOUNCE trial, resulting in withdrawal of olaratumab from the market, illustrate the difficulties in balancing access to novel therapies with the need for proven benefit. (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - June 27, 2019 Category: Cancer & Oncology Source Type: research

Google’s lung cancer AI: a promising tool that needs further validation
Nature Reviews Clinical Oncology, Published online: 27 June 2019; doi:10.1038/s41571-019-0248-7Researchers from Google AI have presented results obtained using a deep learning model for the detection of lung cancer in screening CT images. The authors report a level of performance similar to, or better than, that of radiologists. However, these claims are currently too strong. The model is promising but needs further validation and could only be implemented if screening guidelines were adjusted to accept recommendations from black-box proprietary AI systems. (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - June 27, 2019 Category: Cancer & Oncology Authors: Colin Jacobs Bram van Ginneken Source Type: research

Assessing the interactions between radiotherapy and antitumour immunity
Nature Reviews Clinical Oncology, Published online: 26 June 2019; doi:10.1038/s41571-019-0238-9Despite their promise, immunotherapy–radiotherapy combinations could be limited by the patient-specific nature of radiation-induced immune responses. This Review discusses methods of assessing the immune response to radiotherapy and approaches to predict the synergy between immunotherapy and radiotherapy for personalized medicine. (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - June 26, 2019 Category: Cancer & Oncology Authors: Clemens Grassberger Susannah G. Ellsworth Moses Q. Wilks Florence K. Keane Jay S. Loeffler Source Type: research

BRAF+MEKi and ICI triplets show promise in melanoma
Nature Reviews Clinical Oncology, Published online: 25 June 2019; doi:10.1038/s41571-019-0247-8BRAF+MEKi and ICI triplets show promise in melanoma (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - June 25, 2019 Category: Cancer & Oncology Authors: David Killock Source Type: research

New first-line options in CLL
Nature Reviews Clinical Oncology, Published online: 18 June 2019; doi:10.1038/s41571-019-0243-zNew first-line options in CLL (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - June 18, 2019 Category: Cancer & Oncology Authors: Diana Romero Source Type: research

From the 2019 ASCO Annual Meeting
Nature Reviews Clinical Oncology, Published online: 18 June 2019; doi:10.1038/s41571-019-0245-xFrom the 2019 ASCO Annual Meeting (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - June 18, 2019 Category: Cancer & Oncology Authors: Diana Romero Source Type: research

New daratumumab quadruplets and triplets for newly diagnosed MM
Nature Reviews Clinical Oncology, Published online: 18 June 2019; doi:10.1038/s41571-019-0244-yNew daratumumab quadruplets and triplets for newly diagnosed MM (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - June 18, 2019 Category: Cancer & Oncology Authors: David Killock Source Type: research